...
首页> 外文期刊>Advances in Biochemistry >Heterogeneous Phyto-Antibiotics and Other Future Therapeutics Against Multi-Drug Resistant Bacteria
【24h】

Heterogeneous Phyto-Antibiotics and Other Future Therapeutics Against Multi-Drug Resistant Bacteria

机译:异质植物抗生素和其他针对多药耐药细菌的治疗方法

获取原文

摘要

Phage therapy, enzybiotics, gene medicine and nanodrug-carriers are most vital components of modern research against multidrug-resistant bacteria. Genome evolutionoccurs due to environmental toxicities of various types where soil bacteria are in symbiosis with plant world who secret anti-metabolites against soil bacteria. Gut microbiome secrete vitamins required for our body where as intestinal cells synthesis interleukins and cytokines for symbiotic control of intestinal bacteria. Before the discovery of antibiotic in 1928, peoples trusted plant derived remedies against variety of illness described in Indian Sanskrit books like Charaka Samhita, Sasruta Samhita and Atharva Veda. AMR disease occurred due to repeated but uncontrolled use of antibiotics affecting gut microbiome who acquired many mdr genes in plasmids. We estimated that are 40% of all river and sea water borne bacteria were ampicillin and to lesser extent tetracycline, azithromycin, ciprofloxacin and streptomycin resistant. Where as <1% were multidrug-resistant and ~0.002% Enterobacteriaceae were meropenem, linezolid or amikacin resistant. MDR genes like amp, neo, tet, aac, cat, aph, aad, mcr-1, blaNDM-1, blaKPC-1, arr3, sul1, dhfr, inh, acrAB, mexAB, macAB and mtrCD were amplified with millions mutated isomers increasing all drugs MIC. We studied Indian medicinal plants and spices to get valuable cheap drugs where modified agriculture and/or tissue culture increased the drug concentration. We showed that MDR bacteria were sensitive to organic extract of Suregada multiflora roots, Cassia fistula bark, Jatropha gossypifolia roots as well as Indian spices Labanga and Derchini (MDR-Cure). TLC and HPLC purification as well as UV-VIS, MASS, NMR, FT-IR and XRD-Powder gave many distinct signatures of pure chemicals that also inhibited multidrug-resistant bacteria. Biological targets of 12 chemicals are under investigation targeting DNA Topoisomerase I, DNA Polymerase and RNA Polymerase of Escherichia coli . Indian Government has started Herbal Mission, Ganga Mission and various Plantation Programmes to curve MDR pathogenesis.
机译:噬菌体疗法,酶制剂,基因药物和纳米药物载体是对抗多药耐药细菌的现代研究中最重要的组成部分。基因组进化是由于各种类型的环境毒性而发生的,其中土壤细菌与植物世界共生,而植物界会分泌针对土壤细菌的抗代谢物。肠道微生物组会分泌人体所需的维生素,其中肠道细胞合成白介素和细胞因子以共生控制肠道细菌。在1928年发现抗生素之前,人们一直信任植物衍生的补救措施,以应对印度梵文书籍中描述的各种疾病,例如Charaka Samhita,Sasruta Samhita和Atharva Veda。发生AMR病的原因是重复但不受控制地使用了影响肠道微生物组的抗生素,该肠道微生物组在质粒中获得了许多mdr基因。我们估计,在所有河流和海水传播的细菌中,有40%是氨苄西林,对四环素,阿奇霉素,环丙沙星和链霉素的耐药性较小。其中<1%对多药耐药,〜0.002%肠杆菌科对美洛培南,利奈唑胺或丁胺卡那霉素耐药。 MDR基因,如 amp,neo,tet,aac,cat,aph,aad,mcr-1,blaNDM-1,blaKPC-1,arr3,sul1,dhfr,inh,acrAB,mexAB,macAB和 mtrCD被数以百万计的突变异构体扩增,增加了所有药物的MIC。我们研究了印度药用植物和香料,以获取有价值的廉价药物,其中改良的农业和/或组织培养提高了药物的浓度。我们表明,耐多药细菌对多毛的Suregada multiflora根,决明子瘘皮,麻风树麻风树根以及印度香料Labanga和Derchini(MDR-Cure)的有机提取物敏感。 TLC和HPLC纯化以及UV-VIS,MASS,NMR,FT-IR和XRD-Powder提供了许多纯净化学特征,它们也抑制了耐多药细菌。目前正在研究针对12种化学药品的生物学目标,它们针对大​​肠杆菌的DNA拓扑异构酶I,DNA聚合酶和RNA聚合酶。印度政府已经启动了草药使命,恒河使命和各种种植计划,以改变耐多药的发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号